COPD Independent Risk Factor for Lung Cancer
Risk for lung cancer higher for never smokers with COPD, ever smokers with or without COPD.
Lung Cancer
Lung Cancer News & Features
Osimertinib-Associated Cardiac Toxicity: A Retrospective Study
The incidence of osimertinib-associated grade 3 or higher cardiac adverse events was 4.9% in a retrospective NSCLC population.
Polypharmacy Increases Risk of Post Chemotherapy Inpatient Hospitalization for Older Patients
Patients with cancer aged 65 and older are likely to be taking 5 or more medications before treatment with IV chemotherapy, which can complicate posttreatment care.
Carboplatin Plus Pemetrexed Found Noninferior to Docetaxel in Older Patients With Nonsquamous NSCLC
A phase 3 trial of elderly patients with nonsquamous NSCLC demonstrated that carboplatin + pemetrexed prolonged survival with an improved safety profile compared with docetaxel.
FDA Approves Imfinzi for Extensive-Stage Small Cell Lung Cancer
The approval was based on data from the CASPIAN study, an active-controlled, open-label trial that investigated the combination of durvalumab plus chemotherapy vs chemotherapy alone.
Lung Cancer Clinical Trials
Clinical Trial: Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer
Clinical Trial: Improving Management of Breathlessness in Patients With Lung Cancer
Clinical Trial: Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker
Clinical Trial: Lung Cancer Biomarkers and Screening (NYULCBC)
Clinical Trial: Proton Therapy for Stage I Non-Small Cell Lung Cancer (LU03)
Want to read more?
Please login or register first to view this content.
Next post in Lung Cancer
